# Summary of #hplusroadmap IRC Log (December 3, 2016)

* A discussion about FDA regulations for biosimilar drugs took place, with a participant preparing for a meeting with a senator's office about insulin pricing and regulation issues.

* Participants discussed the ethics of Novo Nordisk's business practices, including allegations that they pulled insulin products from Greece and Germany when price controls were instituted and bribed regulatory officials in China.

* The #WeAreNotWaiting movement was discussed, which focuses on DIY artificial pancreas technology that interfaces insulin pumps with continuous glucose monitors for closed-loop dosing systems (OpenAPS.org).

* Participants debated FDA regulation of DIY medical technology, suggesting that the FDA should have a mandate to help proactive DIY efforts rather than just preventing them, especially for "walking dead" patients with serious conditions.

* A BioViva blog post about dual gene therapy effects on blood biomarkers and muscle composition was shared, indicating ongoing interest in experimental longevity treatments.

* A research paper titled "Alzheimer's disease pathogenesis is dependent on neuronal receptor PTPsigma" was shared from bioRxiv.

* A tool called "timmy" was discussed, which uses a peculiarity in the TLS protocol to enable trusted timestamping by having TLS servers like Google sign hashes with timestamps.

* Security concerns regarding wireless-enabled medical devices were briefly mentioned, noting that vulnerabilities have already been discovered in such devices.